India's Second Indigenous COVID-19 Vaccine Candidate Set for Human Trials, an Industrial Info Market Brief

Indian pharma major Zydus Cadila Healthcare Limited is set to start clinical trials for its COVID-19 vaccine candidate, ZyCoV-D, the country's second indigenously developed vaccine for the novel coronavirus. Drugs Controller General of India (DCGI) on Thursday approved the vaccine for Phase I and II human clinical trials. Zydus Cadila will enroll around 1,000 volunteers across multiple sites for the trials, which will take around three months to be completed.